JMS Co

JMS Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of JMS Co (7702.T) as of Nov 2, 2026 is 113.78 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -1,607.87 % — a change of -107.08% (higher).

FCF Conversion

113.78 %

YoY

-107.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of JMS Co is 2026 113.78 % . FCF Conversion Rate (FCF/EBITDA) of JMS Co was 2025 -1,607.87 % . It decreases by -107.08% higher compared to the previous year.

The JMS Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
117.76 JPY
Jan 1, 2020
13.30 JPY
Jan 1, 2021
27.71 JPY
Jan 1, 2022
137.77 JPY
Jan 1, 2023
-381.14 JPY
Jan 1, 2024
-1,383.33 JPY
Jan 1, 2025
-1,607.87 JPY
Jan 1, 2026
113.78 JPY
The JMS Co FCF Conversion history
YEARFCF ConversionYoY
113.78 %-107.08%
-1,607.87 %+16.23%
-1,383.33 %+262.95%
-381.14 %-376.64%
137.77 %+397.24%
27.71 %+108.28%
13.30 %-88.70%
117.76 %-375.21%
-42.79 %+202.86%
-14.13 %-94.18%
-242.71 %-52.62%
-512.23 %-69.83%
-1,697.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

FCF Conversion Rate (FCF/EBITDA) of JMS Co is 113.78 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of JMS Co changed from -1,607.87 % to 113.78 %, representing a -107.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) JMS Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s JMS Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — JMS Co

All Key Metrics — JMS Co